Expression of the mammalian target of Rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma

Pathobiology

Volumn 79, Issue 2, 2012, Pages 84-93

  Kim, Hyun Soo ^a   Kim, Gou Young ^a   Lim, Sung Jig ^a   Kim, Youn Wha ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

Adenocarcinoma; Lung; mTOR; p70S6K; pAkt; PTEN; Rapamycin; Squamous cell carcinoma

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; S6 KINASE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

MAMMALIA;

EID: 84862804733     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000334340     Document Type: Article

References (35)

1. Travis WD, Brambilia E, Muller-Hermelink HK, Harris CC: Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC Press, 2004.
2. Jung KW, Won YJ, Park S, Kong HJ, Sung J, Shin HR, Park EC, Lee JS: Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci 2009; 24: 995-1003.
3. Vignot S, Faivre S, Aguirre D, Raymond E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525-537. (Pubitemid 40613318)
4. Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, Cappuzzo F, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V: Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009; 20: 1674-1681.
5. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J: Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1603-1610.
6. O'Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1588-1595.
7. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
8. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual. New York, Springer, 2010.
9. Noh WC, Kim YH, Kim MS, Koh JS, Kim HA, Moon NM, Paik NS: Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res Treat 2008; 110: 477-483. (Pubitemid 351962593)
10. Maehama T, Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 13375-13378. (Pubitemid 28268370)
11. Weng L, Brown J, Eng C: PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet 2001; 10: 237-242. (Pubitemid 32123982)
12. Kappes H, Goemann C, Bamberger AM, Loning T, Milde-Langosch K: PTEN expression in breast and endometrial cancer: correlations with steroid hormone receptor status. Pathobiology 2001; 69: 136-142. (Pubitemid 34212084)
13. Tang JM, He QY, Guo RX, Chang XJ: Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006; 51: 181-191.
14. Yoo SB, Xu X, Lee HJ, Jheon S, Lee CT, Choe G, Chung JH: Loss of PTEN expression is an independent poor prognostic factor in nonsmall cell lung cancer. Korean J Pathol 2011; 45: 329-335.
15. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, Khuri FR: Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002; 8: 1178-1184. (Pubitemid 34517656)
16. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, Komminoth P, Lees JA, Mulligan LM, Mutter GL, Eng C: Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999; 155: 1253-1260. (Pubitemid 29488932)
17. Duerr EM, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, Schramm J, Wiestler OD, Parsons R, Eng C, von Deimling A: PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998; 16: 2259-2264. (Pubitemid 28220656)
18. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C: Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92: 924-930.
19. Rowinsky EK: Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 2004; 16: 564-575. (Pubitemid 39482975)
20. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, Gibbons JJ: mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249-258. (Pubitemid 32947647)
21. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, Sawyers CL: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-10319. (Pubitemid 32803017)
22. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F: Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004; 10: 1013-1023. (Pubitemid 38198903)
23. Kobayashi I, Semba S, Matsuda Y, Kuroda Y, Yokozaki H: Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma. Pathobiology 2006; 73: 8-17. (Pubitemid 43952601)
24. Suzuki Y, Shirai K, Oka K, Mobaraki A, Yoshida Y, Noda SE, Okamoto M, Itoh J, Itoh H, Ishiuchi S, Nakano T: Higher pAkt expression predicts a significant worse prognosis in glioblastomas. J Radiat Res (Tokyo) 2010; 51: 343-348.
25. Shi Y, Chen L, Li J, Lv YL, Sun Q, Wang LX, Jiao SC: Prognostic and predictive values of pERK1/2 and pAkt-1 expression in nonsmall cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol 2011; 32: 381-390.
26. Tanaka Y, Terai Y, Tanabe A, Sasaki H, Sekijima T, Fujiwara S, Yamashita Y, Kanemura M, Ueda M, Sugita M, Franklin WA, Ohmichi M: Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer. Cancer Biol Ther 2011; 11: 50-57.
27. Wang X, Yi L, Zhu Y, Zou J, Hong Y, Zheng W: AKT signaling pathway in invasive ductal carcinoma of the breast: correlation with ER ,ER and HER-2 expression. Tumori 2011; 97: 185-190.
28. Dobashi Y, Suzuki S, Matsubara H, Kimura M, Endo S, Ooi A: Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer 2009; 115: 107-118.
29. Hiramatsu M, Ninomiya H, Inamura K, Nomura K, Takeuchi K, Satoh Y, Okumura S, Nakagawa K, Yamori T, Matsuura M, Morikawa T, Ishikawa Y: Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer 2010; 70: 94-102.
30. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, Unger M, Testa JR: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004; 25: 2053-2059. (Pubitemid 39534841)
31. Wullschleger S, Loewith R, Hall MN: TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
32. Thomas GV: mTOR and cancer: reason for dancing at the crossroads? Curr Opin Genet Dev 2006; 16: 78-84. (Pubitemid 43089616)
33. Buck E, Eyzaguirre A, Brown E, Petti F, Mc-Cormack S, Haley JD, Iwata KK, Gibson NW, Griffin G: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006; 5: 2676-2684. (Pubitemid 44848994)
34. Boffa DJ, Luan F, Thomas D, Yang H, Sharma VK, Lagman M, Suthanthiran M: Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 2004; 10: 293-300. (Pubitemid 38114192)
35. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-1508. (Pubitemid 43259931)